These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6581492)

  • 1. Lithium prevents adaptation of brain dopamine systems to haloperidol in schizophrenic patients.
    Sternberg DE; Bowers MB; Heninger GR; Charney DS
    Psychiatry Res; 1983 Oct; 10(2):79-86. PubMed ID: 6581492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
    Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL
    Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium combined with haloperidol in schizophrenic patients.
    Lerner Y; Mintzer Y; Schestatzky M
    Br J Psychiatry; 1988 Sep; 153():359-62. PubMed ID: 3150693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain.
    Reches A; Jackson-Lewis V; Fahn S
    Psychopharmacology (Berl); 1984; 82(4):330-4. PubMed ID: 6427824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma and CSF HVA before and after pharmacological treatment.
    Sharma R; Javaid JI; Janicak P; Faull K; Comaty J; Davis JM
    Psychiatry Res; 1989 Apr; 28(1):97-104. PubMed ID: 2740469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies.
    Beuger M; van Kammen DP; Kelley ME; Yao J
    Neuropsychopharmacology; 1996 Jul; 15(1):75-86. PubMed ID: 8797194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
    Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
    Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of lithium on biochemical manifestations of striatal dopamine target cell supersensitivity induced by prolonged haloperidol treatment.
    Le Douarin C; Oblin A; Fage D; Scatton B
    Eur J Pharmacol; 1983 Sep; 93(1-2):55-62. PubMed ID: 6628547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholecystokinin, dopamine and schizophrenia.
    Garver DL; Beinfeld MC; Yao JK
    Psychopharmacol Bull; 1990; 26(3):377-80. PubMed ID: 2274639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid.
    Labarca R; Silva H; Jerez S; Ruiz A; Forray MI; Gysling K; Andres ME; Bustos G; Castillo Y; Hono J
    Schizophr Res; 1993 Mar; 9(1):29-34. PubMed ID: 8461269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia.
    Fux M; Belmaker RH
    Isr J Psychiatry Relat Sci; 1991; 28(1):37-40. PubMed ID: 1830565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
    Chang WH; Lin SK; Jann MW; Lam YW; Chen TY; Chen CT; Hu WH; Yeh EK
    Biol Psychiatry; 1989 Jul; 26(3):239-49. PubMed ID: 2742942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium dissociates haloperidol-induced behavioral supersensitivity from reduced dopac increase in rat striatum.
    Meller E; Friedman E
    Eur J Pharmacol; 1981 Nov; 76(1):25-9. PubMed ID: 7318921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful combined neuroleptic and lithium treatment of a chronic schizophrenic patient with recurrent aggressive behavior].
    Cabrera JF; Körner W; Müller-Oerlinghausen B
    Nervenarzt; 1986 Jun; 57(6):366-9. PubMed ID: 3736728
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
    Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
    Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs.
    Sedvall G; Fyrö B; Nybäck H; Wiesel FA; Wode-Helgodt B
    J Psychiatr Res; 1974; 11():75-80. PubMed ID: 4461807
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.